LGND Earnings
Latest Revenue63.7M
Latest Net Income48.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $2.42 | 63.7M | 48.5M | +33.7% | +868.0% |
| Q1 2026 | -$0.67 | 51.7M | -13345000 | +14.1% | +69.7% |
| Q4 2025 | $2.33 | 59.7M | 44.8M | +39.4% | +242.1% |
| Q3 2025 | $5.99 | 115.5M | 117.3M | +122.8% | +1,635.9% |
| Q2 2025 | $0.25 | 47.6M | 4.8M | +14.7% | +108.7% |
| Q1 2025 | -$2.21 | 45.3M | -42451000 | +46.3% | -145.5% |
| Q4 2024 | -$1.64 | 42.8M | -31088000 | +52.4% | -257.7% |
| Q3 2024 | -$0.39 | 51.8M | -7172000 | +57.6% | +33.9% |
| Q2 2024 | -$2.88 | 41.5M | -51911000 | — | — |
| Q1 2024 | $4.86 | 31.0M | 86.1M | — | — |
| Q4 2023 | $1.04 | 28.1M | 18.2M | — | — |
| Q3 2023 | -$0.59 | 32.9M | -10273000 | — | — |
Ligand Pharmaceuticals (LGND) — Earnings